Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing technology with high content phenotypic analyses in cultured human cells. The initial project will focus on the in vitro validation of several candidate drug targets chosen by CellCentric to offer high therapeutic anti-cancer potential.
Multi-parametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be adapted to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes across multiple cell lines. The RNAi datasets are said to offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
Christophe Echeverri, CEO of Cenix, said: “We expect that our combination of cutting-edge RNAi with high content cell-based analyses will offer an ideal strategy for advancing the characterization of promising target candidates.